Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJ733 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
NCT02867059Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SJ-733 in malaria (2 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Activity of SJ733 Administered Orally on Clearance of P. Falciparum Blood Stage Parasites From the Blood at Day 28 and Number of Participants With Adverse Events. Started Sep 2016; status: completed.
02
Drugs
SJ-733
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02867059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867059.